A candidate precursor to serous carcinoma that originates in the distal fallopian tube

The tubal fimbria is a common site of origin for early (tubal intraepithelial carcinoma or TIC) serous carcinomas in women with familial BRCA1 or 2 mutations (BRCA+). Somatic p53 tumour suppressor gene mutations in these tumours suggest a pathogenesis involving DNA damage, p53 mutation, and progressive loss of cell cycle control. We recently identified foci of strong p53 immunostaining—termed ‘p53 signatures’—in benign tubal mucosa from BRCA+ women. To examine the relationship between p53 signatures and TIC, we compared location (fimbria vs ampulla), cell type (ciliated vs secretory), evidence of DNA damage, and p53 mutation status between the two entities. p53 signatures were equally common in non‐neoplastic tubes from BRCA+ women and controls, but more frequently present (53%) and multifocal (67%) in fallopian tubes also containing TIC. Like prior studies of TIC, p53 signatures predominated in the fimbriae (80–100%) and targeted secretory cells (HMFG2 + /p73−), with evidence of DNA damage by co‐localization of γ‐H2AX. Laser‐capture microdissected and polymerase chain reaction‐amplified DNA revealed reproducible p53 mutations in eight of 14 fully‐analysed p53 signatures and all of the 12 TICs; TICs and their associated ovarian carcinomas shared identical mutations. In one case, a contiguous p53 signature and TIC shared the same mutation. Morphological intermediates between the two, with p53 mutations and moderate proliferative activity, were also seen. This is the first report of an early and distinct alteration in non‐neoplastic upper genital tract mucosa that fulfils many requirements for a precursor to pelvic serous cancer. The p53 signature and its malignant counterpart (TIC) underline the significance of the fimbria, both as a candidate site for serous carcinogenesis and as a target for future research on the early detection and prevention of this disease. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[2]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[3]  A. Monteiro,et al.  DNA damage response: Determining the fate of phosphorylated histone H2AX , 2006, Cancer biology & therapy.

[4]  Sadir J Alrawi,et al.  Aberrant crypt foci. , 2006, Anticancer research.

[5]  B. Karlan,et al.  BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? , 2005, Obstetrics and gynecology.

[6]  C. Mettlin,et al.  Age-specific ovarian cancer incidence rate patterns in the United States. , 2005, Gynecologic oncology.

[7]  L. Latonen,et al.  Cellular UV damage responses--functions of tumor suppressor p53. , 2005, Biochimica et biophysica acta.

[8]  J. Hayes,et al.  Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. , 2005, Molecular cell.

[9]  A. Strasser,et al.  Death squads enlisted by the tumour suppressor p53. , 2005, Biochemical and biophysical research communications.

[10]  D. Bell,et al.  Current issues in the pathology of ovarian cancer. , 2005, The Journal of reproductive medicine.

[11]  Ming Yang,et al.  High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer. , 2005, Cancer letters.

[12]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[13]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[14]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[15]  Michel Nussenzweig,et al.  H2AX: the histone guardian of the genome. , 2004, DNA repair.

[16]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[17]  J. Boyd,et al.  Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. , 2004, Gynecologic oncology.

[18]  B. Bender,et al.  Adenocarcinoma of the fallopian tube , 2004, Virchows Archiv A.

[19]  B. Stewart,et al.  World Cancer Report , 2003 .

[20]  R. Bast,et al.  Prevention of ovarian cancer: intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  W. Murdoch,et al.  Ovulation-Induced DNA Damage in Ovarian Surface Epithelial Cells of Ewes: Prospective Regulatory Mechanisms of Repair/Survival and Apoptosis1 , 2001, Biology of reproduction.

[22]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[23]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[24]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[25]  F. Pontén,et al.  A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.

[26]  J. Southgate,et al.  Application of a marker of ciliated epithelial cells to gynaecological pathology. , 1999, Journal of clinical pathology.

[27]  J. Southgate,et al.  Induction of a differentiated ciliated cell phenotype in primary cultures of Fallopian tube epithelium. , 1998, Human reproduction.

[28]  F. Pontén,et al.  Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. , 1997, The American journal of pathology.

[29]  M. Wells,et al.  p53 protein expression in putative precursor lesions of epithelial ovarian cancer , 1995, Histopathology.

[30]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[31]  R. Scully,et al.  Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.

[32]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[33]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[34]  J. Gerdes,et al.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.

[35]  M. Friedlander,et al.  Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases , 1989, Cancer.

[36]  T. Fredrickson Ovarian tumors of the hen. , 1987, Environmental health perspectives.